Phio Pharmaceuticals (NASDAQ:PHIO) PT Lowered to $4.00

Phio Pharmaceuticals (NASDAQ:PHIO – Free Report) had its price objective reduced by HC Wainwright from $6.00 to $4.00 in a report released on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q4 2023 earnings at ($1.30) EPS, FY2023 earnings at ($6.26) […]

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States , ,Phio Pharmaceuticals Stock ,Phio Pharmaceuticals ,Phio Pharmaceuticals Corp ,Vanguard Group Inc ,Cambridge Investment Research Advisors Inc ,Nasdaq ,News Ratings For Phio Pharmaceuticals Daily ,Renaissance Technologies ,Institutional Trading Of Phio Pharmaceuticals ,Free Report ,Get Free Report ,Investment Advisers ,Funds Management ,Cambridge Investment Research Advisors ,Natural Killer ,Phio Pharmaceuticals Daily ,Nasdaq Phio ,Ephio ,Medical ,Lower Price Target ,Hc Wainwright ,